For research use only. Not for therapeutic Use.
ZZL-7 is a fast-onset antidepressant agent. ZZL-7 works by disrupting the interaction between the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus (DRN). ZZL-7 can cross the blood-brain barrier readily. ZZL-7 can be used for the research of major depressive disorder (MDD)[1].
ZZL-7 (1.0 μM; or 2 h) incubation of the cultured 293T cells transfected with nNOS and SERT, significantly decreases the SERT-nNOS complex level[1].
ZZL-7 (10 mg/kg, intraperitoneally) causes significantly increases firing frequency of serotonergic neurons 2 hours after treatment in vivo electrophysiology in SERT-Cre mice. In wild-type mice, ZZL-7 reduces immobility time[1].
Intragastric administration of ZZL-7 (10, 20, and 40 mg/kg; once) produces antidepressant-like behaviors dose dependently 2 hours after treatment[1].
ZZL-7 (10 mg/kg; intraperitoneal administration) reverses chronic unpredictable mild stress (CMS)-induced depressions behaviors 2 hours after treatment[1].
| Catalog Number | I042482 |
| CAS Number | 99141-91-0 |
| Synonyms | methyl (2S)-2-[[(2S)-2-acetamidopropanoyl]amino]-3-methylbutanoate |
| Molecular Formula | C11H20N2O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C11H20N2O4/c1-6(2)9(11(16)17-5)13-10(15)7(3)12-8(4)14/h6-7,9H,1-5H3,(H,12,14)(H,13,15)/t7-,9-/m0/s1 |
| InChIKey | RHDUVXUSBMPQOK-CBAPKCEASA-N |
| SMILES | CC(C)C(C(=O)OC)NC(=O)C(C)NC(=O)C |
| Reference | [1]. Nan Sun, et al. Design of fast-onset antidepressant by dissociating SERT from nNOS in the DRN. Science. 2022 Oct 28;378(6618):390-398. |
